European Bioreactor Market size is predicted to reach USD 7 billion by 2028, according to a latest forecast report by Graphical Research.
Over the years, as the prevalence of infectious and chronic diseases increased, so has the need for effective treatments and medicines. The rising burden of CVDs is making biopharmaceutical companies constantly concentrate on the development of new pharmacological therapies. There is a widespread use of bioreactors in product development processes. The demand for pharmaceutical drugs will influence the deployment of bioreactors in the region.
At the beginning of 2020, millions of individuals in the region were impacted by the COVID-19 outbreak, which has altered the demand for immunizations. To prevent a shortage of vaccines and medications, regional market participants are collaborating with other organizations to expand their manufacturing facilities. Governments are also boosting funds to speed up the process of development. For instance, a funding scheme for the creation and distribution of vaccines was launched by the German government.
The reusable bioreactors segment accounted for 75% market share in 2021. Benefits of the products include high-volume production, making them suitable for use in the manufacturing of vaccines and monoclonal antibodies. The issues of volume capacity and product quality prevailing in single-use systems are eliminated in reusable devices. The advantages over single-use systems, including simplicity in scaling up and down during the development process, will foster the industry trends.
In terms of the cells, the adoption of bacterial cells will increase due to their application in the mass manufacture of numerous medicines and enzymes. These cells also have excellent productivity and are less prone to shear damage.
With regards to the molecules, the recombinant proteins vertical segment witness remarkable growth till 2028, driven by the demand for gene-based therapies, with technology advancements and the prevalence of rare disorders. To treat these disorders, numerous businesses are developing novel medications based on recombinant proteins. Recombinant proteins' growing significance in cellular and molecular biology will also have an impact on the market growth.
Browse detailed statistical insights from the report, “Europe Bioreactors Market Forecast 2028 By Product Type (Single-use, Reusable), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By End-use (R&D Organizations, Biopharma Manufacturers, CMOs), Research Report, Country Outlook (Germany, UK, Spain, Italy, France, Netherlands, Denmark, Russia, Poland, Sweden, Norway), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
As per end-users, the R&D organizations segment see massive growth through 2028. The main drivers include a rise in healthcare funding and the need for efficient medical care. Several pharmaceutical companies are spending more on R&D to gain a competitive edge and address the lack of suitable therapeutics in emerging economies. Across the R&D applications, bioreactors offer advantages related to cost and performance.
UK is anticipated to hold over 16% share of Europe bioreactors industry by 2028. Some of the growth-promoting variables include the expanding biotechnology sector, rising healthcare spending, and the existence of large companies. The funding body for bioscience education and research is the Biotechnology and Biological Sciences Research Council (BBSRC). Such funding programs by government organizations encourage the use of cutting-edge products. The COVID-19 pandemic has accelerated the development of medications that will fuel the market expansion.
The bioreactors in European market research report includes in-depth coverage of the industry with estimates & forecast in terms of volume in Kilotons & revenue in USD Million from 2017 to 2028, for the following segments:
Europe Market, By Product Type
Europe Market, By Cell
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
Europe Market, By Molecule
- Monoclonal Antibodies
- Recombinant Proteins
- Stem Cells
- Gene Therapy
Europe Market, By End-use
- Research and Development (R&D) Organizations
- Biopharmaceutical (biopharma) Manufacturers
- Contract Manufacturing Organizations (CMOs)
The above information has been provided for the following countries: